Education
About Us
Working with TipRanks
Follow Us
Infant Bacterial Therapeutics AB (DE:9IB)
FRANKFURT:9IB
9IB Stock Chart & Stats
€4.48
-€0.15(-3.23%)
At close: 4:00 PM EST
€4.48
-€0.15(-3.23%)
Day’s Range― - ―
52-Week Range€2.87 - €7.56
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€69.95M
Enterprise Value€590.21M
Total Cash (Recent Filing)€176.32M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta-0.31
Next Earnings
May 06, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding13,018,137
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-2.50
Price to Book (P/B)4.24
Price to Sales (P/S)180517.03
P/FCF Ratio-6.38
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Infant Bacterial Therapeutics AB News
9IB FAQ
What was Infant Bacterial Therapeutics AB’s price range in the past 12 months?
Infant Bacterial Therapeutics AB lowest stock price was €2.87 and its highest was €7.56 in the past 12 months.
What is Infant Bacterial Therapeutics AB’s market cap?
Infant Bacterial Therapeutics AB’s market cap is €69.95M.
When is Infant Bacterial Therapeutics AB’s upcoming earnings report date?
Infant Bacterial Therapeutics AB’s upcoming earnings report date is May 06, 2026 which is in 80 days.
How were Infant Bacterial Therapeutics AB’s earnings last quarter?
Infant Bacterial Therapeutics AB released its earnings results on Feb 06, 2026. The company reported -€0.135 earnings per share for the quarter, beating the consensus estimate of -€1.205 by €1.07.
Is Infant Bacterial Therapeutics AB overvalued?
According to Wall Street analysts Infant Bacterial Therapeutics AB’s price is currently Overvalued.
Does Infant Bacterial Therapeutics AB pay dividends?
Infant Bacterial Therapeutics AB does not currently pay dividends.
What is Infant Bacterial Therapeutics AB’s EPS estimate?
Infant Bacterial Therapeutics AB’s EPS estimate is -0.13.
How many shares outstanding does Infant Bacterial Therapeutics AB have?
Infant Bacterial Therapeutics AB has 13,018,137 shares outstanding.
What happened to Infant Bacterial Therapeutics AB’s price movement after its last earnings report?
Infant Bacterial Therapeutics AB reported an EPS of -€0.135 in its last earnings report, beating expectations of -€1.205. Following the earnings report the stock price went up 7.425%.
Which hedge fund is a major shareholder of Infant Bacterial Therapeutics AB?
Currently, no hedge funds are holding shares in DE:9IB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, to prevent necrotizing enterocolitis, as well as to improve feeding tolerance affecting premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe disease in infants. The company was founded in 2013 and is based in Stockholm, Sweden.
Technical Analysis
Xbrane Biopharma AB
―
Ascelia Pharma AB
―
Guard Therapeutics International AB
―
Immunicum AB
―
Cantargia AB
―